GlassScriptPhysician profile
Jesus M Hernandez
NPI 1083750913
$11,950.53
in general payments reported to CMS, 2019-2025
33 companies · $863 in 2025
The $863 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $1,261 · 2021: $2,784 · 2022: $2,173 · 2023: $2,028 · 2024: $1,235 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096 · Education: $29.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,096.34 |
| Education | $29.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,316.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,671.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,384.07 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,170.33 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $818.00 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $762.86 | 2020-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $480.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $423.87 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $422.65 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $314.51 | 2020-2023 | |
| Lilly USA, LLC | $254.78 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $244.91 | 2023-2024 | Eliquis, Camzyos |
| Pfizer INC. | $230.86 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $226.37 | 2021 | |
| Neurocrine Biosciences, INC. | $159.99 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $153.40 | 2019-2022 | |
| Amgen INC. | $147.66 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $132.53 | 2019-2023 | Linzess |
| Idorsia Pharmaceuticals US INC | $130.92 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $124.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.43 | 2020 | |
| Sanofi-Aventis U.S. LLC | $46.80 | 2019 | |
| Corium, LLC | $40.14 | 2022-2023 | Adlarity |
| Mannkind Corporation | $39.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $32.06 | 2019 | |
| Ardelyx, INC. | $30.09 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $29.26 | 2025 | Rexulti |
| Activ Surgical, INC. | $25.72 | 2023 | Activsight |
| Bayer Healthcare LLC | $24.23 | 2024 | |
| Aimmune Therapeutics, INC. | $22.79 | 2024 | |
| Lundbeck LLC | $15.79 | 2023 | Rexulti |
| Depuy Synthes Sales INC. | $14.97 | 2023 | Orthovisc |
| Horizon Therapeutics Plc | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.